Alan T Nurden

List of Publications by Year
in descending order

93 papers	6,884 citations	76326 40 h-index	58581 82 g-index
94 all docs	94 docs citations	94 times ranked	6346 citing authors

#	Article	IF	Citations
1	Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature, 2001, 409, 202-207.	27.8	1,338
2	Platelets, inflammation and tissue regeneration. Thrombosis and Haemostasis, 2011, 105, S13-S33.	3.4	593
3	Molecular Defects in Interactions of Platelets with the Vessel Wall. New England Journal of Medicine, 1984, 311, 1084-1098.	27.0	378
4	Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nature Genetics, 2011, 43, 735-737.	21.4	245
5	The gray platelet syndrome: Clinical spectrum of the disease. Blood Reviews, 2007, 21, 21-36.	5.7	201
6	Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood, 2011, 118, 5996-6005.	1.4	194
7	Immunochemical Evidence for Protein Abnormalities in Platelets from Patients with Glanzmann's Thrombasthenia and Bernard-Soulier Syndrome. Journal of Clinical Investigation, 1980, 65, 722-731.	8.2	167
8	A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood, 2016, 127, 2791-2803.	1.4	157
9	Gray platelet syndrome and defective thrombo-inflammation in Nbeal2-deficient mice. Journal of Clinical Investigation, 2013, 123, 3331-3342.	8.2	151
10	Thrombocytopenia resulting from mutations in filamin A can be expressed as an isolated syndrome. Blood, 2011, 118, 5928-5937.	1.4	148
11	Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p. Blood, 2010, 116, 4990-5001.	1.4	137
12	Spectrum of the Mutations in Bernard-Soulier Syndrome. Human Mutation, 2014, 35, 1033-1045.	2.5	124
13	A gain-of-function variant in DIAPH1 causes dominant macrothrombocytopenia and hearing loss. Blood, 2016, 127, 2903-2914.	1.4	121
14	Human phenotype ontology annotation and cluster analysis to unravel genetic defects in 707 cases with unexplained bleeding and platelet disorders. Genome Medicine, 2015, 7, 36.	8.2	119
15	Human CalDAG-GEFI gene (RASGRP2) mutation affects platelet function and causes severe bleeding. Journal of Experimental Medicine, 2014, 211, 1349-1362.	8.5	117
16	A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (Î±IIbÎ²3) integrin receptor locked in a high-affinity state and a Glanzmann thrombastheniaâ€“like phenotype. Blood, 2001, 98, 2432-2441.	1.4	104
17	Platelet-associated CD154 in immune thrombocytopenic purpura. Blood, 2005, 105, 215-218.	1.4	101
18	Relationship between Fibrinogen Binding and the Platelet Glycoprotein Deficiencies in Glanzmann's Thrombasthenia Type I and Type II. British Journal of Haematology, 1981, 48, 47-57.	2.5	99

#	Article	IF	Citations
19	Congenital platelet disorders and understanding of platelet function. British Journal of Haematology, 2014, 165, 165-178.	2.5	99
20	The biology of the platelet with special reference to inflammation wound healing and immunity. Frontiers in Bioscience - Landmark, 2018, 23, 726-751.	3.0	97
21	Autologous fibrin scaffolds: When platelet- and plasma-derived biomolecules meet fibrin. Biomaterials, 2019, 192, 440-460.	11.4	92
22	Absence of GPIbÎ± is responsible for aberrant membrane development during megakaryocyte maturation. Experimental Hematology, 2002, 30, 352-360.	0.4	86
23	Glanzmann Thrombasthenia: State of the Art and Future Directions. Seminars in Thrombosis and Hemostasis, 2013, 39, 642-655.	2.7	84
24	Defects in TRPM7 channel function deregulate thrombopoiesis through altered cellular Mg2+ homeostasis and cytoskeletal architecture. Nature Communications, 2016, 7, 11097.	12.8	84
25	Severe deficiency of glycoprotein VI in a patient with gray platelet syndrome. Blood, 2004, 104, 107-114.	1.4	83
26	Mutation spectrum and genotypeâ€phenotype correlations in a large French cohort of <scp>MYH</scp>9â€Related Disorders. Molecular Genetics & Genomic Medicine, 2014, 2, 297-312.	1.2	78
27	Procoagulant Platelets Form an Î±-Granule Protein-covered â€œCapâ€•on Their Surface That Promotes Their Attachment to Aggregates. Journal of Biological Chemistry, 2013, 288, 29621-29632.	3.4	74
28	Abnormal VWF modifies megakaryocytopoiesis: studies of platelets and megakaryocyte cultures from patients with von Willebrand disease type 2B. Blood, 2010, 115, 2649-2656.	1.4	71
29	Expanding the Mutation Spectrum Affecting Î±IIbÎ²3 Integrin in Glanzmann Thrombasthenia: Screening of theITGA2BandITGB3Genes in a Large International Cohort. Human Mutation, 2015, 36, 548-561.	2.5	67
30	New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet, The, 2009, 373, 1562-1569.	13.7	65
31	Tissue inhibitors of matrix metalloproteinases in platelets and megakaryocytes: A novel organization for these secreted proteins. Experimental Hematology, 2009, 37, 849-856.	0.4	61
32	A Novel Leukocyte Adhesion Deficiency III Variant: Kindlin-3 Deficiency Results in Integrin- and Nonintegrin-Related Defects in Different Steps of Leukocyte Adhesion. Journal of Immunology, 2011, 186, 5273-5283.	0.8	59
33	Platelet Glycoprotein IIb/IIIa Inhibitors. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2835-2840.	2.4	57
34	Labeling of the Internal Pool of GP IIb-IIIa in Platelets by c7E3 Fab Fragments (abciximab): Flow and Endocytic Mechanisms Contribute to the Transport. Blood, 1999, 93, 1622-1633.	1.4	56
35	Glanzmann Thrombasthenia-Like Syndromes Associated with Macrothrombocytopenias and Mutations in the Genes Encoding the Î±IIbÎ²3 Integrin. Seminars in Thrombosis and Hemostasis, 2011, 37, 698-706.	2.7	53
36	Heterogeneity of Platelet Functional Alterations in Patients With Filamin A Mutations. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, e11-8.	2.4	52

#	Article	IF	Citations
37	A Cdc42/RhoA regulatory circuit downstream of glycoprotein Ib guides transendothelial platelet biogenesis. Nature Communications, 2017, 8, 15838.	12.8	50
38	Two Types of Procoagulant Platelets Are Formed Upon Physiological Activation and Are Controlled by Integrin Î± _{IIb} Î² ₃. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2475-2483.	2.4	46
39	Activation of Î±IIbÎ²3 is a sufficient but also an imperative prerequisite for activation of Î±2Î²1 on platelets. Blood, 2007, 109, 595-602.	1.4	43
40	Understanding the genetic basis of Glanzmann thrombasthenia: implications for treatment. Expert Review of Hematology, 2012, 5, 487-503.	2.2	42
41	Inherited thrombocytopenias: history, advances and perspectives. Haematologica, 2020, 105, 2004-2019.	3.5	42
42	Characterization of Inherited Differences in Transcription of the Human Integrin Î±2 Gene. Journal of Biological Chemistry, 2001, 276, 23518-23524.	3.4	41
43	Ultrastructural analysis of the distribution of the vitronectin receptor (Î± v Î² 3) in human platelets and megakaryocytes reveals an intracellular pool and labelling of the Î±â€granule membrane. British Journal of Haematology, 1997, 96, 823-835.	2.5	38
44	Î±IIbÎ²3 variants defined by next-generation sequencing: Predicting variants likely to cause Glanzmann thrombasthenia. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1898-907.	7.1	36
45	Clinical significance of altered collagen-receptor functioning in platelets with emphasis on glycoprotein VI. Blood Reviews, 2019, 38, 100592.	5.7	35
46	Inherited platelet diseases with normal platelet count: phenotypes, genotypes and diagnostic strategy. Haematologica, 2021, 106, 337-350.	3.5	35
47	Two human antibodies reacting with different epitopes on integrin beta3 of platelets and endothelial cells. FEBS Journal, 1994, 222, 743-751.	0.2	33
48	Founder effect and estimation of the age of the French Gypsy mutation associated with Glanzmann thrombasthenia in Manouche families. European Journal of Human Genetics, 2011, 19, 981-987.	2.8	33
49	PAICA: A Method for Characterizing Platelet-Associated Antibodies - Its Application to the Study of Idiopathic Thrombocytopenic Purpura and to the Detection of Platelet-bound c7E3. Thrombosis and Haemostasis, 1996, 76, 1020-1029.	3.4	33
50	ITGA2B and ITGB3 gene mutations associated with Glanzmann thrombasthenia. Platelets, 2018, 29, 98-101.	2.3	32
51	Human IgG Monoclonal Anti-Î±IIbÎ²3-Binding Fragments Derived from Immunized Donors Using Phage Display. Journal of Immunology, 2002, 168, 2035-2045.	0.8	30
52	Phosphatidylserine exposure and other apoptoticâ€like events in Bernardâ€Soulier syndrome platelets. American Journal of Hematology, 2010, 85, 584-592.	4.1	29
53	Homozygous Cys542Arg substitution in GPIIIa in a Swiss patient with type I Glanzmann's thrombasthenia. British Journal of Haematology, 1999, 105, 523-531.	2.5	28
54	Distribution of glycoprotein IIb-IIIa complexes in the surface membranes of human platelets and megakaryocytes. British Journal of Haematology, 1985, 59, 171-182.	2.5	27

#	Article	IF	Citations
55	Double heterozygosity of the GPIIb gene in a Swiss patient with Glanzmann's thrombasthenia. British Journal of Haematology, 1998, 102, 918-925.	2.5	27
56	Analysis of the Amino Acid Requirement for a Normal Î±IIbÎ²3 Maturation at Î±IIbGlu324 Commonly Mutated in Glanzmann Thrombasthenia. Thrombosis and Haemostasis, 2002, 88, 655-662.	3.4	25
57	Should any genetic defect affecting Î±â€granules in platelets be classified as gray platelet syndrome?. American Journal of Hematology, 2016, 91, 714-718.	4.1	25
58	Thrombocytopenia after abciximab use results from different mechanisms. Thrombosis and Haemostasis, 2010, 103, 651-661.	3.4	23
59	Should studies on Glanzmann thrombasthenia not be telling us more about cardiovascular disease and other major illnesses?. Blood Reviews, 2017, 31, 287-299.	5.7	21
60	Marked bleeding diathesis in patients with platelet dysfunction due to a novel mutation in RASGRP2, encoding CalDAG-GEFI (p.Gly305Asp). Platelets, 2018, 29, 84-86.	2.3	20
61	Acquired Glanzmann thrombasthenia: From antibodies to anti-platelet drugs. Blood Reviews, 2019, 36, 10-22.	5.7	20
62	A novel 196 Leu to Pro substitution in the Î²3 subunit of the Î±IIbÎ²3 integrin in a patient with a variant form of Glanzmann thrombasthenia. Platelets, 2002, 13, 101-111.	2.3	18
63	Detection of Transfused Platelets in a Patient with Glanzmann Thrombasthenia. Thrombosis and Haemostasis, 2002, 87, 543-544.	3.4	18
64	Bilateral linkage between a new deletion polymorphism in intron 21 of the GP lib gene and the HPA-3b (Bakb) determinant. British Journal of Haematology, 1995, 91, 747-751.	2.5	17
65	Mutations of the integrin Î±IIb/Î²3 intracytoplasmic salt bridge cause macrothrombocytopenia and enlarged platelet Î±â€granules. American Journal of Hematology, 2018, 93, 195-204.	4.1	17
66	A novel variant Glanzmann thrombasthenia due to co-inheritance of a loss- and a gain-of-function mutation of ITGB3 : evidence of a dominant effect of gain-of-function mutations. Haematologica, 2018, 103, e259-e263.	3.5	16
67	Phenotype analysis and clinical management in a large family with a novel truncating mutation in RASGRP2, the CalDAGâ€GEFI encoding gene. Research and Practice in Thrombosis and Haemostasis, 2017, 1, 128-133.	2.3	14
68	A Glanzmann thrombasthenia family associated with a TUBB1â€related macrothrombocytopenia. Journal of Thrombosis and Haemostasis, 2019, 17, 2211-2215.	3.8	14
69	Autoimmune thrombocytopenic purpura (AITP) and acquired thrombasthenia due to autoantibodies to GP IIbâ€“IIIa in a patient with an unusual platelet membrane glycoprotein composition. , 1998, 57, 164-175.		13
70	An intracytoplasmic Î²3 Leu718 deletion in a patient with a novel platelet phenotype. Blood Advances, 2017, 1, 494-499.	5.2	13
71	Linkage disequilibrium amongst <scp>ITGA</scp>2B and <scp>ITGB</scp>3 gene variants in patients with Glanzmann thrombasthenia confirms that most diseaseâ€causing mutations are recent. British Journal of Haematology, 2016, 175, 686-695.	2.5	12
72	A Ser752â†'Pro substitution in the cytoplasmic domain of Î²3 in a Glanzmann thrombasthenia variant fails to prevent interactions between the Î±IIbÎ²3 integrin and the platelet granule pool of fibrinogen. British Journal of Haematology, 2002, 118, 1143-1151.	2.5	11

#	Article	IF	Citations
73	Rapid diagnosis of the French gypsy mutation in Glanzmann thrombasthenia using high-resolution melting analysis. Thrombosis and Haemostasis, 2010, 104, 1076-1077.	3.4	11
74	Acquired Antibodies to Î± IIbÎ²3 in Glanzmann Thrombasthenia: From Transfusion and Pregnancy to Bone Marrow Transplants and Beyond. Transfusion Medicine Reviews, 2018, 32, 155-164.	2.0	10
75	High-throughput sequencing for rapid diagnosis of inherited platelet disorders: a case for a European consensus. Haematologica, 2018, 103, 6-8.	3.5	8
76	Molecular Dynamics Analysis of a Novel Î²3 Pro189Ser Mutation in a Patient with Glanzmann Thrombasthenia Differentially Affecting Î±IIbÎ²3 and Î±vÎ²3 Expression. PLoS ONE, 2013, 8, e78683.	2.5	7
77	Deep Vein Thrombosis, Raynaud's Phenomenon, and Prinzmetal Angina in a Patient with Glanzmann Thrombasthenia. Case Reports in Hematology, 2012, 2012, 1-4.	0.4	6
78	In silico analysis of structural modifications in and around the integrin Î±<scp>II</scp>b genu caused by <scp>ITGA</scp>2B variants in human platelets with emphasis on Glanzmann thrombasthenia. Molecular Genetics & Genomic Medicine, 2018, 6, 249-260.	1.2	6
79	A novel amino acid substitution of integrin Î±IIb in Glanzmann thrombasthenia confirms that the N-terminal region of the receptor plays a role in maintaining Î²-propeller structure. Platelets, 2013, 24, 77-80.	2.3	5
80	Phosphatidylserine exposure, microparticle formation and mitochondrial depolarisation in Glanzmann thrombasthenia platelets. Thrombosis and Haemostasis, 2014, 111, 1184-1186.	3.4	5
81	Healing through the lens of immunothrombosis: Biology-inspired, evolution-tailored, and human-engineered biomimetic therapies. Biomaterials, 2021, 279, 121205.	11.4	5
82	Screening for factor V Leiden and a prothrombin gene polymorphism in patients with Glanzmann's thrombasthenia. British Journal of Haematology, 1998, 101, 593-594.	2.5	4
83	Management of pregnancy for a patient with the new syndromic macrothrombocytopenia, DIAPH1-related disease. Platelets, 2018, 29, 737-738.	2.3	4
84	More than 500Âmillion years of evolution in a fibrin-based therapeutic scaffold. Regenerative Medicine, 2020, 15, 1493-1498.	1.7	4
85	Reduced Collagen-Induced Platelet Aggregation in Obligate Heterozygotes of a Glanzmann Thrombasthenia Variant with a Î²3 Mutation. Thrombosis and Haemostasis, 2002, 88, 364-365.	3.4	3
86	Are bone defects in rare patients with Glanzmann's thrombasthenia associated withITGB3orITGA2Bmutations?. Platelets, 2011, 22, 547-551.	2.3	3
87	Is the mysterious platelet receptor GPV an unsuspected major target for platelet autoantibodies?. Haematologica, 2019, 104, 1103-1105.	3.5	3
88	Profiling the Genetic and Molecular Characteristics of Glanzmann Thrombasthenia: Can It Guide Current and Future Therapies?. Journal of Blood Medicine, 2021, Volume 12, 581-599.	1.7	3
89	Analysis of the amino acid requirement for a normal alphaIIbbeta3 maturation at alphaIIbGlu324 commonly mutated in Glanzmann thrombasthenia. Thrombosis and Haemostasis, 2002, 88, 655-62.	3.4	3
90	A unique combination of inhibitory and partially activating mutations in Î²3 of a patient with variant-type Glanzmann thrombasthenia. Platelets, 2010, 21, 498-500.	2.3	2

#	Article	IF	Citations
91	Personal reflections on the early contributions of Gus Born to platelet research. Platelets, 2018, 29, 756-760.	2.3	1
92	Reduced collagen-induced platelet aggregation in obligate heterozygotes of a Glanzmann thrombasthenia variant with a beta 3 mutation. Thrombosis and Haemostasis, 2002, 88, 364-5.	3.4	1
93	Platelets: 25 years under the editorship of Stan Heptinstall. Platelets, 2015, 26, 378-381.	2.3	0